Twist Bioscience Corporation Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $0.00.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $2.36M, a 2.92% decline year-over-year.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $1.78M, a 3.84% increase year-over-year.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $0.00.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for fiscal 2025 was $4.21M, a 11.90% increase from fiscal 2024.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for fiscal 2024 was $3.77M, a 4.37% decline from fiscal 2023.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for fiscal 2023 was $3.94M, a 1.82% decline from fiscal 2022.
- Twist Bioscience Corporation stock issued during period, value, employee stock purchase plan for fiscal 2022 was $4.01M, a 18.89% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | |
| 2026-03-31 | $2.36M 10-Q · filed 2026-05-04 | |
| 2025-09-30 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $4.21M 10-K · filed 2025-11-17 |
| 2025-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | |
| 2025-03-31 | $2.43M 10-Q · filed 2026-05-04 | |
| 2024-09-30 | $1.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $3.77M 10-K · filed 2025-11-17 |
| 2024-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-04 | |
| 2024-03-31 | $2.05M 10-Q · filed 2025-05-05 | |
| 2023-09-30 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $3.94M 10-K · filed 2025-11-17 |
| 2023-06-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | |
| 2023-03-31 | $2.54M 10-Q · filed 2023-05-08 | |
| 2022-09-30 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $4.01M 10-K · filed 2024-11-18 |
| 2022-06-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | |
| 2022-03-31 | $2.40M 10-Q · filed 2023-05-08 | |
| 2021-09-30 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $4.94M 10-K · filed 2023-11-21 |
| 2021-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | |
| 2021-03-31 | $2.79M 10-Q · filed 2022-05-06 | |
| 2020-09-30 | $1.91M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $3.43M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | |
| 2020-03-31 | $1.52M 10-Q · filed 2021-05-07 | |
| 2019-09-30 | $2.70M 10-K · filed 2021-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |